Pegvisomant

Generic Name: Pegvisomant

Brand Names: Somavert

Drug Type: Biotech

Chemical Formula: -

CAS Number: 218620-50-9

Unique Ingredient Identifier: N824AOU5XV

Background: Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.

Indication: Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.

Associated Conditions: Acromegaly

Associated Therapies: -

Clinical Trials

Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance

Phase 2

Recruiting

Conditions: Partial Lipodystrophy
Insulin Receptor Mutation

Interventions: Drug: Pegvisomant

First Posted Date: 2022-07-22

Last Posted Date: 2024-05-21

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 25

Registration Number: NCT05470504

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess

Phase 3

Recruiting

Conditions: Pituitary Disease

Interventions: Drug: Pegvisomant

First Posted Date: 2019-03-20

Last Posted Date: 2024-12-19

Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Target Recruit Count: 120

Registration Number: NCT03882034

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Bone MicroArchitecture in Acromegaly

Completed

Conditions: Osteoporosis Risk
Acromegaly

Interventions: Drug: Pegvisomant

First Posted Date: 2017-07-21

Last Posted Date: 2021-07-13

Lead Sponsor: Columbia University

Target Recruit Count: 77

Registration Number: NCT03225040

Locations: 🇺🇸
Neuroendocrine Unit and Pituitary Center, Columbia University, New York, New York, United States

Strict IGF-1 Control in Acromegaly

Phase 3

Completed

Conditions: Acromegaly

Interventions: Drug: Pegvisomant

First Posted Date: 2016-11-02

Last Posted Date: 2021-11-22

Lead Sponsor: Unity Health Toronto

Target Recruit Count: 10

Registration Number: NCT02952885

Locations: 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦
St. Joseph Health Care London, London, Ontario, Canada
🇨🇦
Centre hospitalier universitaire de Québec-Université Laval, Quebec City, Quebec, Canada

and more 2 locations

Pasireotide LAR and Pegvisomant Study in Acromegaly

Phase 4

Conditions: Acromegaly

Interventions: Drug: Pasireotide LAR 60 mg
Drug: Pegvisomant

First Posted Date: 2016-01-29

Last Posted Date: 2016-08-03

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 60

Registration Number: NCT02668172

Locations: 🇳🇱
Erasmus Medical Center, Rotterdam, South Holland, Netherlands

Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting

Not Applicable

Completed

Conditions: Healthy

Interventions: Other: Fasting
Drug: Saline
Drug: Pegvisomant

First Posted Date: 2015-07-16

Last Posted Date: 2016-11-23

Lead Sponsor: University of Aarhus

Target Recruit Count: 10

Registration Number: NCT02500095

Locations: 🇩🇰
Aarhus University Hospital, Aarhus, Denmark

Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes

Phase 2

Completed

Conditions: Diabetes
Metabolic Syndrome
Insulin Resistance

Interventions: Drug: pegvisomant

First Posted Date: 2013-12-30

Last Posted Date: 2017-04-24

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 6

Registration Number: NCT02023918

Locations: 🇺🇸
San Francisco General Hospital, San Francisco, California, United States

Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency

Not Applicable

Conditions: Adults Growth Hormone Deficiency.

Interventions: Drug: Pegvisomant
Drug: Regular insulin

First Posted Date: 2013-03-05

Last Posted Date: 2013-10-24

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 10

Registration Number: NCT01804413

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Effect of DPP4 Inhibition on Growth Hormone Secretion

Phase 4

Completed

Conditions: Obesity

Interventions: Drug: Sitagliptin
Drug: Placebo
Drug: Pegvisomant
Drug: Exendin 9-39
Drug: L-NMMA

First Posted Date: 2012-10-05

Last Posted Date: 2018-05-29

Lead Sponsor: Vanderbilt University

Target Recruit Count: 44

Registration Number: NCT01701973

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Acromegaly Combination Treatment Study

Not Applicable

Terminated

Conditions: Acromegaly

Interventions: Drug: Pegvisomant
Drug: Octreotide LAR
Drug: Lanreotide

First Posted Date: 2012-02-27

Last Posted Date: 2023-01-04

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 76

Registration Number: NCT01538966

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy